About CoTherix
CoTherix is a Healthcare company based in San Francisco (United States) founded in 2000, and was acquired by Actelion in November 2006. Inhaled therapeutics for cardiopulmonary diseases were developed and licensed. CoTherix has raised $55 million across 1 funding round from investors including Actelion, Frazier Healthcare Partners and Thomas Weisel Partners. Its focus areas include Life Sciences, Pulmonology, Drugs and Pulmonary Arterial Hypertension. Its competitors include Aerovate Therapeutics, Vivus and Centessa Pharmaceuticals; 2 of its 3 listed competitors have raised funding.
Company details
CoTherix was established in 2000 in San Francisco, United States, within the biopharmaceutical sector. Therapeutics targeting cardiopulmonary and chronic diseases were licensed and developed by the company. Operations centered on inhaled treatments, including Ventavis (iloprost), approved for pulmonary arterial hypertension. The firm was acquired by Actellion in January 2007, concluding its independent activities.
- Headquarters San Francisco, United States
- Stage Acquired
- SectorsHealthcare
- Website cotherix.com
- Acquired by Actelion (Nov 2006)
Funding Insights of CoTherix
CoTherix has successfully raised a total of $55M through 1 strategic funding round. The most recent funding activity was a Series C round of $55 million completed in October 2003. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $55M
- Total Rounds 1
- Last Round Series C — $55M
- First Round $55M
(Oct 2003)
- Investors Count 8
All 1 funding rounds of CoTherix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2003 | $55M | Series C | – | – |
9 investors in total: 9 institutional.
Investors in CoTherix
CoTherix has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Actelion, Frazier Healthcare Partners and Thomas Weisel Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Life Sciences sector focused early stage VC firm investing primarily in Europe | sofinnova.fr | Paris, France | ||
| spraypartners.com | ||||
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
Wealth management services are provided to high-net-worth clients. | 1999 | tweisel.com | San Francisco, United States | |
Innovative treatments for orphan diseases are discovered, developed, and commercialized. | 1997 | actelion.com | Allschwil, Switzerland |
Investor details for CoTherix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of CoTherix
4 dated milestones of CoTherix across 6 years, from founding to its latest funding, stage changes and deals.
- Founded CoTherix is founded.
- Funding First funding round of $55.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Actelion.
Competitors of CoTherix
CoTherix has 3 listed competitors in our database, 2 of them funded. They include Aerovate Therapeutics, Vivus and Centessa Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aerovatetx.com | 2018 | Boston, United States | $75.82M | 31 | Therapeutic solutions for pulmonary arterial hypertension are developed. | |
| vivus.com | 1991 | Mountain View, United States | 59 | Developer of therapeutic solutions for obesity and sexual health | ||
| centessa.com | 2021 | Boston, United States | $250M | 83 | Medicines for sleep-wake, neurological, neurodegenerative, and psychiatric disorders are developed. |
Detailed competitors of CoTherix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pulmonology
3 companies that operate in the same segment as CoTherix (Pulmonology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | 329 | ||
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cotherix
Complete news archive for CoTherix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CoTherix
CoTherix was founded in 2000 and raised its 1st funding round 3 years after it was founded.
CoTherix is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
CoTherix is a funded company, having raised a total of $55M across 1 funding round to date. The company's 1st funding round was a Series C of $55M, raised on Oct 2003.
CoTherix was established in 2000 in San Francisco, United States, within the biopharmaceutical sector. Therapeutics targeting cardiopulmonary and chronic diseases were licensed and developed by the company. Operations centered on inhaled treatments, including Ventavis (iloprost), approved for pulmonary arterial hypertension. The firm was acquired by Actellion in January 2007, concluding its independent activities.
CoTherix's top competitors include Aerovate Therapeutics, Vivus and Centessa Pharmaceuticals.
CoTherix has 9 investors. Key investors include Actelion, Frazier Healthcare Partners, Thomas Weisel Partners, Turmeric Acquisition Corp, and Sofinnova.
Yes. CoTherix was acquired by Actelion in November 2006.